Our aims are to identify genomic regions in SE negative individuals that may act independently of the SE in RA development, to evaluate any potential effect modification or epistasis with HLA-DRβ1 in SE positive individuals, and to identify new genomic regions associated with the continuous phenotypes of RFUW and anti-CCP. The gene discussed is HLA-DRB1; the disease is rheumatoid arthritis.